On December 18, 2025, Pulse Biosciences, Inc. announced FDA approval for its Investigational Device Exemption (IDE) to start the NANOPULSE-AF clinical study, which will involve up to 145 patients across 30 sites to test a new cardiac catheter system for treating atrial fibrillation.